Bausch Health Companies Inc. (BHC): Price and Financial Metrics

Bausch Health Companies Inc. (BHC)

Today's Latest Price: $24.79 USD

1.66 (-6.28%)

Updated Jan 27 7:00pm

Add BHC to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

BHC Stock Summary

  • Bausch Health Companies Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 97.79% of US listed stocks.
  • BHC's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 99.26% of US stocks.
  • Over the past twelve months, BHC has reported earnings growth of -155.52%, putting it ahead of merely 12.64% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Bausch Health Companies Inc are ATLC, KFS, HCHC, SEAS, and COMM.
  • BHC's SEC filings can be seen here. And to visit Bausch Health Companies Inc's official web site, go to

BHC Stock Price Chart Interactive Chart >

Price chart for BHC

BHC Price/Volume Stats

Current price $24.79 52-week high $29.68
Prev. close $26.45 52-week low $11.15
Day low $24.57 Volume 8,264,600
Day high $26.14 Avg. volume 4,840,612
50-day MA $21.64 Dividend yield N/A
200-day MA $18.54 Market Cap 8.80B

Bausch Health Companies Inc. (BHC) Company Bio

Bausch Health Cos. Inc. (formerly) Valeant Pharmaceuticals is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices, including contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. The company was founded in 1983 and is based in Laval, Canada.

BHC Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$24.79$1.83 -93%

Below please find a table outlining a discounted cash flow forecast for BHC, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Bausch Health Companies Inc ranked in the 10th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for BHC, they are:

  • In the past 5.52 years, Bausch Health Companies Inc has a compound free cash flow growth rate of -0.17%; that's better than just 8.96% of cash flow producing equities in the Healthcare sector, where it is classified.
  • 28% of the company's capital comes from equity, which is greater than only 7.86% of stocks in our cash flow based forecasting set.
  • Bausch Health Companies Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.3. This coverage rate is greater than that of only 24.31% of stocks we're observing for the purpose of forecasting via discounted cash flows.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as BHC, try EW, SRDX, COO, RHE, and OSMT.

BHC Latest News Stream

Event/Time News Detail
Loading, please wait...

BHC Latest Social Stream

Loading social stream, please wait...

View Full BHC Social Stream

Latest BHC News From Around the Web

Below are the latest news stories about Bausch Health Companies Inc that investors may wish to consider to help them evaluate BHC as an investment opportunity.

Tetra Pak calls for collaborative innovation to tackle sustainability challenges in the food packaging industry

LAUSANNE, Switzerland, Jan. 25, 2021 /CNW/ -- Tetra Pak has introduced a new collaborative innovation model with leading paperboard producers, a move aimed at tackling the food packaging industry's sustainability challenges.

Yahoo | January 25, 2021

Bausch Health gets Piper Sandler downgrade; weakness of diversified unit cited

Piper Sandler has downgraded to Bausch Health (BHC) to neutral from overweight questioning the cashflow resilience of the company’s pharmaceutical business.The analysts led by David Amsellem have however raised the price target to ~$30 from $25. Bausch shares are trading ~0.5% higher today.Announced in August, the diversified pharmaceutical unit of Bausch was...

Seeking Alpha | January 22, 2021

Applications are Now Open for the 2021-2022 William Southam Journalism Fellowships

TORONTO, Jan. 22, 2021 /CNW/ - Applications are now open for the 2021-2022 William Southam Journalism Fellowships.

Yahoo | January 22, 2021

Bausch + Lomb's Lumify eye drops OK'd in South Korea

Bausch Health (BHC) unit, Bausch + Lomb announces that Lumify (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops have received approval in South Korea. "LUMIFY will be a welcome addition to our portfolio of eye health products in South Korea, and we expect LUMIFY will be available to consumers in...

Seeking Alpha | January 21, 2021

South Korea's MFDS Approves LUMIFY® Eye Drops

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that LUMIFY® (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops have received approval from the Ministry of Food and Drug Safety (MFDS) in South Korea.

Yahoo | January 21, 2021

Read More 'BHC' Stories Here

BHC Price Returns

1-mo 24.51%
3-mo 50.24%
6-mo 35.69%
1-year -14.96%
3-year 27.85%
5-year -72.52%
YTD 19.18%
2020 -30.48%
2019 61.99%
2018 -11.12%
2017 43.11%
2016 -85.72%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8508 seconds.